Please ensure Javascript is enabled for purposes of website accessibility

A COVID-19 Immunity Test Is on the Way

By Joe Tenebruso - Mar 25, 2020 at 7:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You may soon be able to know if you're immune to the coronavirus.

Scientists are devising a new weapon against the COVID-19 pandemic.

New blood tests could soon tell you if you're immune to the potentially deadly disease caused by the novel coronavirus.

Multiple companies and academic institutions are working to produce tests that can detect certain antibodies in people who were infected with the disease but were asymptomatic.

Identifying those people who are better able to withstand the disease could help to bring about an array of positive developments. For one, doctors and nurses who are immune would be better able to treat sick patients, since they would be less likely to need to be quarantined if exposed to COVID-19. For another, people who are immune could be among the first who return to work. This, in turn, could help to fill a vital need for workers in essential industries like medical equipment manufacturing, food production, and supply delivery.

"Ultimately, this [antibody test] might help us figure out who can get the country back to normal," Florian Krammer, a professor at the Mount Sinai Icahn School of Medicine, told Reuters. "People who are immune could be the first people to go back to normal life and start everything up again."

A person drawing an upwardly sloping line labeled immunity.

New blood tests could soon help you determine if you're immune to COVID-19. Image source: Getty Images.

Several private U.S.-based companies, such as Biomerica and Chembio Diagnostics, have already begun to sell blood tests for COVID-19 antibodies in international markets. The tests use blood from a finger prick and are easy to administer. They're also relatively inexpensive, with some costing less than $10. And some of these tests can deliver results in as little as 10 minutes.

The U.S. Centers for Disease Control and Prevention is also developing its own antibody test, but the federal government might choose to allow the use of other tests if the CDC's version is not ready soon.

But there is still a lot of uncertainty and risk surrounding these tests. Health officials don't yet know how long immunity to COVID-19 lasts. There are also questions regarding the accuracy of the tests. Moreover, it's not yet known if immunity would provide enough protection to people who are constantly exposed to the virus, such as in hospitals.

Still, these immunity tests could go a long way toward helping the U.S. and other countries around the world restart their economies, and would allow many people to begin to return to a more normal way of life.

And as for people who are not immune to COVID-19, hope remains that an effective treatment will be found soon. Biotechnology giant Gilead Sciences' (GILD 0.89%) experimental drug remdesivir is perhaps our best hope in this regard. Remdesivir showed promise in animal models for treating MERS and SARS, which are also caused by coronaviruses that are structurally similar to COVID-19, indicating that the drug may have potential as a treatment for COVID-19.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.36 (0.89%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.